Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Structure-based optimization of cyclopropyl urea derivatives as potent soluble epoxide hydrolase inhibitors for potential decrease of renal injury without hypotensive action.

Takai K, Nakajima T, Takanashi Y, Sone T, Nariai T, Chiyo N, Nakatani S, Ishikawa C, Yamaguchi N, Fujita K, Yamada K.

Bioorg Med Chem. 2014 Mar 1;22(5):1548-57. doi: 10.1016/j.bmc.2014.01.040. Epub 2014 Jan 31.

PMID:
24530032
2.

Three-dimensional rational approach to the discovery of potent substituted cyclopropyl urea soluble epoxide hydrolase inhibitors.

Takai K, Chiyo N, Nakajima T, Nariai T, Ishikawa C, Nakatani S, Ikeno A, Yamamoto S, Sone T.

Bioorg Med Chem Lett. 2015 Apr 15;25(8):1705-1708. doi: 10.1016/j.bmcl.2015.02.076. Epub 2015 Mar 7.

PMID:
25800114
3.

Role of haem oxygenase in the renoprotective effects of soluble epoxide hydrolase inhibition in diabetic spontaneously hypertensive rats.

Elmarakby AA, Faulkner J, Pye C, Rouch K, Alhashim A, Maddipati KR, Baban B.

Clin Sci (Lond). 2013 Oct;125(7):349-59. doi: 10.1042/CS20130003.

PMID:
23611540
4.

Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.

Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, Zeldin DC, Kroetz DL.

Circ Res. 2000 Nov 24;87(11):992-8.

5.

Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase.

Eldrup AB, Soleymanzadeh F, Farrow NA, Kukulka A, De Lombaert S.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):571-5. doi: 10.1016/j.bmcl.2009.11.091. Epub 2009 Nov 22.

PMID:
19969453
6.

Discovery of 2,8-diazaspiro[4.5]decane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating hypertension.

Kato Y, Fuchi N, Saburi H, Nishimura Y, Watanabe A, Yagi M, Nakadera Y, Higashi E, Yamada M, Aoki T.

Bioorg Med Chem Lett. 2013 Nov 1;23(21):5975-9. doi: 10.1016/j.bmcl.2013.08.054. Epub 2013 Aug 20.

PMID:
24035338
7.

Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.

Shen HC, Ding FX, Deng Q, Xu S, Chen HS, Tong X, Tong V, Zhang X, Chen Y, Zhou G, Pai LY, Alonso-Galicia M, Zhang B, Roy S, Tata JR, Berger JP, Colletti SL.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5314-20. doi: 10.1016/j.bmcl.2009.07.138. Epub 2009 Aug 6.

PMID:
19682899
8.

Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.

Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, Imig JD.

J Am Soc Nephrol. 2004 May;15(5):1244-53.

9.

Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats.

Ghosh S, Chiang PC, Wahlstrom JL, Fujiwara H, Selbo JG, Roberds SL.

Basic Clin Pharmacol Toxicol. 2008 May;102(5):453-8. doi: 10.1111/j.1742-7843.2008.00213.x. Epub 2008 Feb 29.

10.

Discovery of 1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating of chronic kidney diseases.

Kato Y, Fuchi N, Nishimura Y, Watanabe A, Yagi M, Nakadera Y, Higashi E, Yamada M, Aoki T, Kigoshi H.

Bioorg Med Chem Lett. 2014 Jan 15;24(2):565-70. doi: 10.1016/j.bmcl.2013.12.020. Epub 2013 Dec 10.

PMID:
24373724
11.
12.

Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension.

Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock BD, Imig JD.

Am J Physiol Renal Physiol. 2009 Sep;297(3):F740-8. doi: 10.1152/ajprenal.00098.2009. Epub 2009 Jun 24.

13.

Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.

Revermann M.

Curr Opin Pharmacol. 2010 Apr;10(2):173-8. doi: 10.1016/j.coph.2009.12.002. Epub 2010 Jan 14. Review.

PMID:
20079692
14.

Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles.

Gauthier KM, Olson L, Harder A, Isbell M, Imig JD, Gutterman DD, Falck JR, Campbell WB.

Am J Physiol Renal Physiol. 2011 Oct;301(4):F765-72. doi: 10.1152/ajprenal.00201.2011. Epub 2011 Jul 13.

15.

Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension.

Neckář J, Kopkan L, Husková Z, Kolář F, Papoušek F, Kramer HJ, Hwang SH, Hammock BD, Imig JD, Malý J, Netuka I, Ošťádal B, Červenka L.

Clin Sci (Lond). 2012 Jun;122(11):513-25. doi: 10.1042/CS20110622.

16.

Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase.

Loch D, Hoey A, Morisseau C, Hammock BO, Brown L.

Cell Biochem Biophys. 2007;47(1):87-98.

17.

Omeprazole increases the efficacy of a soluble epoxide hydrolase inhibitor in a PGE₂ induced pain model.

Goswami SK, Inceoglu B, Yang J, Wan D, Kodani SD, da Silva CA, Morisseau C, Hammock BD.

Toxicol Appl Pharmacol. 2015 Dec 15;289(3):419-27. doi: 10.1016/j.taap.2015.10.018. Epub 2015 Nov 10.

18.

Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor κB signaling.

Liu Y, Webb HK, Fukushima H, Micheli J, Markova S, Olson JL, Kroetz DL.

J Pharmacol Exp Ther. 2012 Jun;341(3):725-34. doi: 10.1124/jpet.111.191247. Epub 2012 Mar 13.

19.

Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension.

Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD.

Hypertension. 2002 Feb;39(2 Pt 2):690-4.

20.

Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.

Shen HC, Ding FX, Wang S, Xu S, Chen HS, Tong X, Tong V, Mitra K, Kumar S, Zhang X, Chen Y, Zhou G, Pai LY, Alonso-Galicia M, Chen X, Zhang B, Tata JR, Berger JP, Colletti SL.

Bioorg Med Chem Lett. 2009 Jul 1;19(13):3398-404. doi: 10.1016/j.bmcl.2009.05.036. Epub 2009 May 18.

PMID:
19481932

Supplemental Content

Support Center